Edward A. Stadtmauer

faculty photo
Professor of Medicine at the Hospital of the University of Pennsylvania
Co-Leader, Hematologic Malignancies Program, University of Pennsylvania Abramson Cancer Center
Co-Leader, Hematologic Malignancies Translational Center of Excellence, Penn Medicine/Abramson Cancer Center
Chief, Section of Hematologic Malignancies, Division of Hematology-Oncology, Department of Medicine
Department: Medicine

Contact information
2 Perelman Center for Advanced Medicine
34th and Civic Center Bld
Philadelphia, PA 19104
Office: 2156627910
Fax: 215-662-4064
A.B. (Biochemistry)
Cornell University, College of Arts and Sciences, 1979.
M.D. (Medicine)
University of Pennsylvania School of Medicine, 1983.
Permanent link

Description of Research Expertise

Clinical trials, Bone Marrow Transplant

Description of Itmat Expertise

Dr. Stadtmauer is pursuing new treatment approaches to improve the long term survival of patients with leukemia, lymphoma, myeloma and those undergoing bone marrow transplant.

Selected Publications

Waxman, A J; Mick, R; Garfall, A L; Cohen, A; Vogl, D T; Stadtmauer, E A; Weiss, B M.: Classifying ultra-high risk smoldering myeloma. Leukemia 29(3): 751-3, Mar 2015.

Stadtmauer, Edward A; Sullivan, Keith M; Marty, Francisco M; Dadwal, Sanjeet S; Papanicolaou, Genovefa A; Shea, Thomas C; Mossad, Sherif B; Andreadis, Charalambos; Young, Jo-Anne H; Buadi, Francis K; El Idrissi, Mohamed; Heineman, Thomas C; Berkowitz, Elchonon M.: A phase 1/2 study of an adjuvanted varicella-zoster virus subunit vaccine in autologous hematopoietic cell transplant recipients. Blood 124(19): 2921-9, Nov 6 2014.

Alsina, Melissa; Becker, Pamela S; Zhong, Xiaobo; Adams, Alexia; Hari, Parameswaran; Rowley, Scott; Stadtmauer, Edward A; Vesole, David H; Logan, Brent; Weisdorf, Daniel; Qazilbash, Muzaffar; Popplewell, Leslie L; McClune, Brian; Bensinger, William; Riches, Marcie; Giralt, Sergio A; Pasquini, Marcelo C; Resource for Clinical Investigation in Blood and Marrow Transplantation.: Lenalidomide maintenance for high-risk multiple myeloma after allogeneic hematopoietic cell transplantation. Biology of Blood & Marrow Transplantation 20(8): 1183-9, Aug 2014.

Vogl, Dan T; Stadtmauer, Edward A; Tan, Kay-See; Heitjan, Daniel F; Davis, Lisa E; Pontiggia, Laura; Rangwala, Reshma; Piao, Shengfu; Chang, Yunyoung C; Scott, Emma C; Paul, Thomas M; Nichols, Charles W; Porter, David L; Kaplan, Janeen; Mallon, Gayle; Bradner, James E; Amaravadi, Ravi K.: Combined autophagy and proteasome inhibition: a phase 1 trial of hydroxychloroquine and bortezomib in patients with relapsed/refractory myeloma. Autophagy 10(8): 1380-90, Aug 2014.

Rapoport Aaron P, Aqui Nicole A, Stadtmauer Edward A, Vogl Dan T, Xu Yin Yan, Kalos Michael, Cai Ling, Fang Hong-Bin, Weiss Brendan M, Badros Ashraf, Yanovich Saul, Akpek Gorgun, Tsao Patricia, Cross Alan, Mann Dean, Philip Sunita, Kerr Naseem, Brennan Andrea, Zheng Zhaohui, Ruehle Kathleen, Milliron Todd, Strome Scott E, Salazar Andres M, Levine Bruce L, June Carl H: Combination immunotherapy after ASCT for multiple myeloma using MAGE-A3/Poly-ICLC immunizations followed by adoptive transfer of vaccine-primed and costimulated autologous T cells. Clinical cancer research : an official journal of the American Association for Cancer Research 20(5): 1355-65, Mar 2014.

Chng W J, Dispenzieri A, Chim C-S, Fonseca R, Goldschmidt H, Lentzsch S, Munshi N, Palumbo A, Miguel J S, Sonneveld P, Cavo M, Usmani S, Durie B G M, Avet-Loiseau H: IMWG consensus on risk stratification in multiple myeloma. Leukemia 28(2): 269-77, Feb 2014.

Mulligan George, Lichter David I, Di Bacco Alessandra, Blakemore Stephen J, Berger Allison, Koenig Erik, Bernard Hugues, Trepicchio William, Li Bin, Neuwirth Rachel, Chattopadhyay Nibedita, Bolen Joseph B, Dorner Andrew J, van de Velde Helgi, Ricci Deborah, Jagannath Sundar, Berenson James R, Richardson Paul G, Stadtmauer Edward A, Orlowski Robert Z, Lonial Sagar, Anderson Kenneth C, Sonneveld Pieter, San Miguel Jesús F, Esseltine Dixie-Lee, Schu Matthew: Mutation of NRAS but not KRAS significantly reduces myeloma sensitivity to single-agent bortezomib therapy. Blood 123(5): 632-9, Jan 2014.

Micallef Ivana N, Stiff Patrick J, Stadtmauer Edward A, Bolwell Brian J, Nademanee Auayporn P, Maziarz Richard T, Partisano Angela M, Marulkar Sachin, DiPersio John F: Safety and efficacy of upfront plerixafor + G-CSF versus placebo + G-CSF for mobilization of CD34(+) hematopoietic progenitor cells in patients ≥60 and <60 years of age with non-Hodgkin's lymphoma or multiple myeloma. American journal of hematology 88(12): 1017-23, Dec 2013.

Jakubowiak A J, Siegel D S, Martin T, Wang M, Vij R, Lonial S, Trudel S, Kukreti V, Bahlis N, Alsina M, Chanan-Khan A, Buadi F, Reu F J, Somlo G, Zonder J, Song K, Stewart A K, Stadtmauer E, Harrison B L, Wong A F, Orlowski R Z, Jagannath S: Treatment outcomes in patients with relapsed and refractory multiple myeloma and high-risk cytogenetics receiving single-agent carfilzomib in the PX-171-003-A1 study. Leukemia 27(12): 2351-6, Dec 2013.

Kaufman Jonathan L, Niesvizky Ruben, Stadtmauer Edward A, Chanan-Khan Asher, Siegel David, Horne Heather, Wegener William A, Goldenberg David M: Phase I, multicentre, dose-escalation trial of monotherapy with milatuzumab (humanized anti-CD74 monoclonal antibody) in relapsed or refractory multiple myeloma. British journal of haematology 163(4): 478-86, Nov 2013.

back to top
Last updated: 08/04/2015
The Trustees of the University of Pennsylvania